Streetbeat News

EPIX

ESSA Pharma Inc.

https://www.essapharma.com

Industry

Biotechnology

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Open

1.74

Mkt cap

78M

Volume

29K

High

1.79

P/E Ratio

-2.84

52-wk high

11.67

Low

1.73

Div yield

N/A

52-wk low

1.40

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. (NASDAQ:EPIX) for potential violations of federal securities laws. This follows ESSA's announcement on October 31, 2024, that it is ending its Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 18, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. for potential securities fraud violations. This follows ESSA's announcement of ending its Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. (NASDAQ:EPIX) for potential violations of federal securities laws. This follows ESSA's announcement of ending its Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 12, 2024 | 12:45 pm

Portfolio Pulse from

November 11, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. (NASDAQ:EPIX) for potential violations of federal securities laws following the company's decision to end its Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 08, 2024 | 12:45 pm

Portfolio Pulse from

November 06, 2024 | 3:45 pm

Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. for potential securities fraud violations following the company's decision to end a Phase 2 trial for a prostate cancer treatment.

Portfolio Pulse from

November 05, 2024 | 3:45 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ESSA Pharma Inc. (NASDAQ:EPIX) shareholders. Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 05, 2024 | 3:15 pm

Portfolio Pulse from

November 05, 2024 | 12:30 pm

U.S. stocks rose with the Nasdaq Composite gaining over 100 points. Apple shares fell 2% despite beating Q4 earnings estimates. ChromaDex, Proto Labs, and Interface saw significant stock price increases after positive financial results. ESSA Pharma, Myriad Genetics, and Lexicon Pharmaceuticals experienced sharp declines due to negative news.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 6:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.